China's Centre for Disease Control Director Gao Fu admitted in a press conference that Chinese vaccines do not have high protection rates and hence they might have to be mixed to provide a boost.
“It's now under formal consideration whether we should use different vaccines from different technical lines for the immunisation process,” the official was quoted as saying by the Associated Press.
For example, the Covid-19 vaccine made by Chinese developer Sinovac has shown a meagre prevention rate of 50.4 per cent in terms of preventing symptomatic infections. Moreover, Gao even hinted at considering the advantages of the m-RNA vaccines, though he had himself raised concerns over its safety back in December.
He claimed that it should be utilised carefully and not ignored merely because numerous types of vaccines are already available. Beijing has supplied several of its indigenously-developed vaccines across the world and has also prohibited the use of any international vaccine in China.
Sequential immunisation along with mixture of vaccines are said to shoot up their effectiveness. Hence, certain researchers in Britain are also deliberating upon possibly combining the Pfizer and AstraZeneca vaccines to avail better returns.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.